环孢素治疗葡萄膜炎:改变格局还是风险选择?系统综述与荟萃分析评估其疗效与安全性
该系统综述与荟萃分析纳入16项研究共943例葡萄膜炎患者,评估环孢素疗效与安全性。环孢素使约79%患者视力改善或稳定,约77%患者眼内炎症得到控制,但仅约43%患者达到完全缓解;疲劳(约65%)、肾毒性(57%)和高血压(21%)常见。
要点
- 环孢素治疗使约79%葡萄膜炎患者视力改善或稳定,约77%患者眼内炎症得到控制。
- 仅约43%患者达到完全疾病缓解,提示环孢素有效控制活动但未必诱导长期缓解。
- 肾毒性(57%)和高血压(21%)常见,治疗期间需定期监测肾功能和血压。
核心结论
- 环孢素对非感染性葡萄膜炎有显著疗效,约79%患者视力改善、77%患者炎症控制,但仅43%达到完全缓解。
- 肾毒性(57%)和高血压(21%)等不良事件常见,长期使用需个体化风险获益评估。
- 环孢素是有效的保视力激素节约型免疫抑制剂。
研究设计与样本
- 系统综述与荟萃分析,检索PubMed、Science Direct、Dimensions和Google Scholar数据库至2025年2月7日。
- 遵循PRISMA指南和PICOS框架,纳入随机对照试验、队列研究和病例系列。
- 最终纳入16项研究共943例患者,采用Cochrane RoB 2、ROBINS-I、JBI和Newcastle-Ottawa量表评估偏倚风险和质量。
主要发现
- 视力改善或稳定的事件率为0.879(95%CI 0.832至0.914,p<0.0001,I²=0%),约79%患者。
- 眼内炎症控制的事件率为0.767(95%CI 0.705至0.818,p<0.0001,I²=0%),约77%患者。
- 完全疾病缓解的事件率为0.43(95%CI 0.39至0.48,p=0.044),约43%患者。
- 疲劳是最常见不良事件,影响约65%患者;肾毒性(血清肌酐升高)见于57%患者;高血压见于约21%患者。
- 所有主要结局的异质性可忽略(I²=0%),发表偏倚评估为极小。
临床怎么用
- 环孢素可作为非感染性葡萄膜炎的有效激素节约型免疫抑制剂用于视力保护。
- 治疗期间需定期监测肾功能和血压。
- 长期使用需个体化风险获益评估。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Uveitis, an inflammation of the uveal tract, can lead to severe ocular complications and vision loss if left untreated. Cyclosporine has gained recognition as an effective immunosuppressive therapy, particularly as a steroid-sparing agent. This study aims to evaluate the efficacy and safety of cyclosporine in managing various types of uveitis, assess its safety profile and associated adverse effects, and compare its therapeutic effectiveness to other treatment options. METHODS: Systematic review and meta-analysis were conducted on PubMed, Science Direct, Dimensions and Google Scholar databases through 7 February 2025. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines were followed, and the Population, Intervention, Comparison, Outcomes, Study Design framework was observed with the inclusion criteria. Eligible studies included randomised controlled trials, cohort studies and case series that assessed cyclosporine use for any form of uveitis. Outcomes included improvement in visual acuity, inflammation control, remission rates and adverse events (nephrotoxicity, hypertension, fatigue). Risk of bias was assessed using the Cochrane RoB 2 tool for Randomized Control Trials and Risk of Bias for the Non-Randomized Interventional studies for non-randomised studies. Quality was evaluated using the Joanna Briggs Institute Critical Appraisal Checklist for case-control studies for case series studies evaluation, and Newcastle-Ottawa Scale for cohort studies. RESULTS: A total of 57 703 studies were identified through database searching. After removal of duplicates and application of inclusion and exclusion criteria, 16 studies encompassing 943 patients were included in the final analysis. The meta-analysis demonstrated that cyclosporine therapy resulted in significant visual acuity improvement or stabilisation in approximately 79% of patients (event rate=0.879; 95% CI 0.832 to 0.914; p<0.0001; I²=0%), reflecting a robust and consistent therapeutic benefit. Control of intraocular inflammation was achieved in approximately 77% of patients (event rate=0.767; 95% CI 0.705 to 0.818; p<0.0001; I²=0%), underscoring cyclosporine's efficacy in managing inflammatory activity. However, complete disease remission was achieved in only about 43% of patients (event rate=0.43; 95% CI 0.39 to 0.48; p=0.044), indicating that while cyclosporine effectively controls disease activity, it does not consistently induce long-term remission. Adverse effects were common and clinically significant. Fatigue was the most frequently reported adverse event, affecting approximately 65% of patients. Nephrotoxicity, indicated by elevated serum creatinine, was observed in 57% of patients, highlighting the critical need for regular renal monitoring during therapy. Hypertension developed in about 21% of patients, necessitating periodic blood pressure assessment. Importantly, heterogeneity across the studies for all major outcomes was negligible (I²=0%), and publication bias was assessed as minimal, lending further credibility to the pooled estimates. CONCLUSION: Cyclosporine demonstrates significant efficacy in the management of non-infectious uveitis, improving visual acuity in approximately 79% of patients and achieving inflammation control in 77%. However, complete remission was attained in only 43% of cases. Adverse events, notably nephrotoxicity (57%) and hypertension (21%), were frequent and highlight the need for careful monitoring. These findings affirm cyclosporine's role as an effective steroid-sparing immunosuppressive agent for vision preservation, though its long-term use requires individualised risk-benefit evaluation. PROSPERO REGISTRATION NUMBER: CRD42025644344.
引用
- Chen KY, Chan HC, Chan CM, et al. Cyclosporine in uveitis: a game changer or a risky choice? A systematic review and meta-analysis of its efficacy and safety. Br J Ophthalmol. 2025. PMID: 40812793. doi:10.1136/bjo-2025-327349
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。